{"id":51568,"date":"2021-09-01T05:12:33","date_gmt":"2021-09-01T05:12:33","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=78063"},"modified":"2021-09-01T05:12:33","modified_gmt":"2021-09-01T05:12:33","slug":"nyxoah-issues-first-half-2021-financial-results","status":"publish","type":"post","link":"https:\/\/kuwaitnewsgazette.com\/nyxoah-issues-first-half-2021-financial-results\/","title":{"rendered":"Nyxoah Issues First Half 2021 Financial Results"},"content":{"rendered":"
REGULATED INFORMATION<\/strong><\/p>\n Nyxoah Issues First Half 2021 Financial Results<\/strong><\/p>\n Mont-Saint-Guibert, Belgium \u2013 August 31, 2021, 10:30pm CET \/ 4:30pm ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH)<\/strong>(\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced its unaudited condensed consolidated interim financial statements for the first half of 2021.<\/p>\n Highlights<\/strong><\/p>\n \u201cIn the first half of 2021, we kept pace with our initiatives to deliver significant new accomplishments.\u00a0\u00a0In less than 12 months, we completed our second IPO with a Nasdaq listing, further strengthening our balance sheet; made important gains in commercial activities in Germany, our initial commercial proof of concept market; advanced clinical programs, including data to potentially expand our addressable market to include CCC patients; and maintained focused investments in new products and technologies,\u201d said Olivier Taelman, CEO of Nyxoah.\u00a0\u00a0\u201cIn the second half, we look forward to further accelerating our commercial activities in existing markets, enter new markets, scale up, and advance clinical programs, including enrollment completion of our US DREAM study in the fourth quarter.\u201d<\/p>\n First Half 2021 Results<\/strong><\/p>\n\n